It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day.

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

AbbVie has had a dramatic year, juggling a Humira hangover, political landmines, and a costly failed drug trial. Despite a major flop on a $9 billion acquisition, AbbVie’s new immunology duo, Skyrizi ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

American pharmaceutical company AbbVie has marked its entry into the Indian cancer drugs segment with Venetoclax used to treat Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL).